Upstream Bio (UPB) Depreciation & Amortization (CF) (2023 - 2026)
Upstream Bio (UPB) posted quarterly Depreciation & Amortization (CF) of $49000.0 for Q1 2026, up 13.95% year-over-year from $43000.0 in Q1 2025, and down 14.04% quarter-over-quarter from $57000.0 in Q4 2025.
Upstream Bio (UPB) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Upstream Bio's Depreciation & Amortization (CF) history runs 4 years deep, the most recent figure standing at $49000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 13.95% year-over-year to $49000.0; the TTM figure through Mar 2026 stood at $306000.0 (up 4.79% YoY), while the FY2025 annual figure was $188000.0, up 111.24% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $49000.0, down from $57000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $100000.0 in Q3 2023, with the low at $13000.0 in Q1 2024.
- The 4-year median for Depreciation & Amortization (CF) is $57000.0 (2025), against an average of $65909.1.
- Peak annual rise in Depreciation & Amortization (CF) reached 250.0% in 2024, while the deepest fall reached 0.0% in 2024.
- Upstream Bio's Depreciation & Amortization (CF) stood at $14000.0 in 2023, then jumped by 250.0% to $49000.0 in 2024, then advanced by 16.33% to $57000.0 in 2025, then decreased by 14.04% to $49000.0 in 2026.
- Business Quant data shows UPB's Depreciation & Amortization (CF) at $49000.0 in Q1 2026, $57000.0 in Q4 2025, and $100000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100,000.00 |
| Jun 30, 2026 | 100,000.00 |
| Mar 31, 2026 | 49,000.00 |
| Mar 31, 2026 | 49,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Mar 31, 2024 | 13,000.00 |